April 1, 2023
The following revisions were incorporated into the April 1, 2023 update.
Additions Genetically and bio-engineered skin substitutes for wound care A2019 - Kerecis omega3 marigen shield, per square centimeter A2021 - Neomatrix, per square centimeter Q4265 - Neostim tl, per square centimeter Q4266 - Neostim membrane, per square centimeter Q4267 - Neostim dl, per square centimeter Q4268 - Surgraft ft, per square centimeter Q4269 - Surgraft xt, per square centimeter Q4270 - Complete sl, per square centimeter Q4271 - Complete ft, per square centimeter Antineoplastic agents Elahere™ - C9146 Imjudo® - C9147, J3490, and J3590 Lunsumio™ - J3590 and C9399 Pemfexy™ - J9304, J9314, J9294, J9296, J9297 Tecvayli™ - C9148 Vegzelma® - Q5129 Endocrine/metabolic agents Tzield™ - C9149 and J3590 Xenpozyme™ - J0218 Gene Replacement / Gene Editing Therapies Hemgenix® - J1411 Immunological agents Spevigo® - J1747 Multiple sclerosis agents Briumvi™ - J3590 and C9399 Neutropenia Fylnetra® - Q5130 Rolvedon™ - J1449 Stimufend® - Q5127 Ophthalmic agents Cimerli™ - Q5128
____________________________________________________________________
Deletions
Antineoplastic agents Elahere™ - J3490, J3590, and C9399 Mosunetuzumab (pending FDA approval) - J3490, J3590, and C9399 Pemetrexed – J9314 Tremelimumab (pending FDA approval) - J3490, J3590, and C9399 Gene Replacement / Gene Editing Therapies Etranacogene Dezaparvovec (pending FDA approval) - J3490, J3590, and C9399 Immunological agents Spevigo® - J3590 and C9399 Multiple sclerosis agents Ublituximab (pending FDA approval) - J3490, J3590, and C9399 Neutropenia Fylnetra® - J3590 and C9399 Rolvedon™ - J3490 and C9399 Stimufend® - J3590 and C9399 Ophthalmic agents Cimerli™ - J3490, J3590, and C9399 Miscellaneous therapeutic agents Teplizumab (pending FDA approval) - C9399 and J3590 |